SynthesisWorld journal of gastroenterology2010
A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
Synthesis in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- ESPGHAN/NASPGHAN guidelines for treatment of irritable bowel syndrome and functional abdominal pain-not otherwise specified in children aged 4-18 years.Journal of pediatric gastroenterology and nutrition · 2025Guideline
- Herbal medicines for the management of irritable bowel syndrome: a comprehensive review.World journal of gastroenterology · 2012Pooled it
- Irritable bowel syndrome.BMJ clinical evidence · 2012Pooled it
- Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope?World journal of gastroenterology · 2011Pooled it
- Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial.BioMed research international · 2014Trial
- Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: A randomized double-blind controlled study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationTrial
- Comparative Effectiveness of Mebeverine and Otilonium Bromide on Health-Related Quality of Life in Patients with Irritable Bowel Syndrome: A Prospective Cohort Study.Life (Basel, Switzerland) · 2026Article
- Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Review
- Chronic Abdominal Discomfort Syndrome (CADS): A Narrative Review of Treatment Strategies.Journal of pain research · 2025Article
- 2-Amino-Molecules (Basel, Switzerland) · 2024Article
- In Silico, In Vitro, and Ex Vivo Biological Activity of Some Novel Mebeverine Precursors.Biomedicines · 2023Article
- Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.United European gastroenterology journal · 2022Review
- The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review.Journal of clinical medicine · 2022Review
- Article
- Management of pouch related symptoms in patients who underwent ileal pouch anal anastomosis surgery for adenomatous polyposis.World journal of clinical cases · 2021Article
- Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?Journal of family medicine and primary care · 2019Article
- Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition.Journal of neurogastroenterology and motility · 2018Review
- Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.Therapeutic advances in gastroenterology · 2017Review
- The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).Therapeutic advances in gastroenterology · 2015Review
- Childhood functional abdominal pain: mechanisms and management.Nature reviews. Gastroenterology & hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the efficacy and tolerability of mebeverine, a musculotropic antispasmodic agent, in irritable bowel syndrome (IBS) and compared its usual dosages by meta-analysis. Medical databases and all relevant literature were searched from 1965 to June 2009 for any placebo-controlled clinical trials of mebeverine, using search terms such as mebeverine, clinical trials, and IBS. Eight randomized trials met our criteria, including six trials that compared mebeverine with placebo and two that compared mebeverine tablets with capsules. These eight trials included 555 patients randomized to receive either mebeverine or placebo with 352 (63%) women and 203 (37%) men in all subtypes of IBS. The pooled relative risk (RR) for clinical improvement of mebeverine was 1.13 (95% CI: 0.59-2.16, P = 0.7056) and 1.33 (95% CI: 0.92-1.93, P = 0.129) for relief of abdominal pain. The efficacy of mebeverine 200 mg compared to mebeverine 135 mg indicated RRs of 1.12 (95% CI: 0.96-1.3, P = 0.168) for clinical or global improvement and 1.08 (95% CI: 0.87-1.34, P = 0.463) for relief of abdominal pain. Thus, mebeverine is mostly well tolerated with no significant adverse effects; however, its efficacy in global improvement of IBS is not statistically significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.